Visiongain Report Researches Growth Opportunities Within the $49 bn Asthma & COPD Market

Visiongain Report Researches Growth Opportunities Within the $49 bn Asthma & COPD Market

PR Newswire

LONDON, March 19, 2020

- Pharma Leader Series: Top 26 Asthma & COPD Companies 2020-2030

- Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

LONDON, March 19, 2020 /PRNewswire/ -- The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $60.8bn by 2030.

Visiongain Logo

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 177-page report you will receive 100 charts– all unavailable elsewhere.

The 177-page Visiongain report provides clear detailed insight into the Top 26 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at or refer to our website: 

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2020-2030

• Profiles of the leading 26 asthma & COPD companies:
• Adamis Pharmaceuticals Corporation
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• Dimerix
• GlaxoSmithKline
• Innoviva
• Lallemand Pharma International
• Merck
• Mereo BioPharma Group plc
• MundiPharma
• Novartis
• Pulmatrix
• Respiratorius AB
• Roche
• Other companies

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company's marketed product and product pipeline
• Financial Information
• Revenue forecast from 2020-2030
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

• Key questions answered by this report:
• How is the Asthma & COPD Companies market evolving?
• What is driving and restraining the Asthma & COPD Companies market?
• What are the market shares of each segment of the overall Asthma & COPD Companies market in 2019?
• What will be the main driver for the overall market from 2019 to 2030?
• Will leading Asthma & COPD Companies broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
• What are the predictions for M&A activity, consolidation for existing players and the potential prospects for new market entrants?
• How will the industry evolve during the period between 2019 and 2030?

To request a report overview of this report please contact Sara Peerun at or refer to our website:

Did you know that we also offer a report add-on service? Email to discuss any customized research needs you may have.

Companies covered in the report include:

Aerocrine (Circassia)
ALK-Abello A/S
American College of Chest Physicians (ACCP)
Amphastar Pharmaceuticals, Inc.
Boehringer Ingelheim
Chiesi Farmaceutici
Committee for Medicinal Products for Human Use (CHMP)
Dainippon Sumitomo Pharma America, Inc.
Dermira Inc.
European Medicines Agency (EMA)
European Respiratory Society (ERS)
GlaxoSmithKline (GSK)
Innovata plc
Innoviva, Inc.
Japanese Ministry of Health, Labour and Welfare
Lallemand Pharma International
Medicines and Healthcare products Regulatory Agency (MHRA)
Monitored Therapeutics, Inc. (MTI)
National Institute for Health and Care Excellence (NICE)
Sepracor Inc.
Theravance Biopharma|Mylan Inc.
Vectura Group plc
Verona Pharma plc

To see a report overview please e-mail Sara Peerun on

Related reports:

Global Asthma & COPD Therapies Market 2019-2029

The Global Respiratory Inhalers Market 2020-2030

Top 55 Pharmaceutical Contract Manufacturing Organisations (CMOs) Market 2020

Top 20 Global Respiratory Inhalers Manufacturers 2019

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029


Voltar noticias em Inglês